These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12928941)

  • 1. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].
    Rubbert-Roth A; Perniok A
    Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM; Schechtman J; Bennett R; Handel ML; Burmester GR; Tesser J; Modafferi D; Poulakos J; Sun G
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the safety of anakinra in patients with rheumatoid arthritis.
    Fleischmann RM
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii29-35. PubMed ID: 12817093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
    Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anakinra: new preparation. Weakly effective in rheumatoid arthritis.
    Prescrire Int; 2004 Apr; 13(70):43-5. PubMed ID: 15148945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bringing the clinical experience with anakinra to the patient.
    Cohen SB; Rubbert A
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii36-40. PubMed ID: 12817094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
    Kary S; Burmester GR
    Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC; Cohen S; Moreland L; Lium D; Robbins S; Newmark R; Bekker P;
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra: interleukin-1 receptor antagonist therapy for rheumatoid arthritis.
    Garces K
    Issues Emerg Health Technol; 2001 May; (16):1-4. PubMed ID: 11776280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis.
    Dayer JM
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii3-10. PubMed ID: 12817089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist].
    Suzuki T
    Nihon Rinsho; 2002 Dec; 60(12):2397-400. PubMed ID: 12510368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mode of action of cytokine inhibitors.
    Arend WP
    J Rheumatol Suppl; 2002 Sep; 65():16-21. PubMed ID: 12236617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
    Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
    Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.